CNBC March 29, 2025
Key Points
– Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial.
– The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four years on average in patients with diabetes and established heart disease, with or without chronic kidney disease.
– The results pave the way for it to become a new treatment option for people living with diabetes and established heart disease.
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease.
The pill lowered the risk...
Today's Sponsors
Today's Sponsor